作为非小细胞肺癌预后标志物的细胞周期蛋白依赖性磷酸酶25B（cdc25B）基因的表达

Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer.

作者信息

Sasaki H, Yukiue H, Kobayashi Y, Tanahashi M, Moriyama S, Nakashima Y, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y

机构信息

Department of Surgery II, Nagoya City University Medical School, 1 Kawasumi, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan.

出版信息

Cancer Lett. 2001 Nov 28;173(2):187-92. doi: 10.1016/s0304-3835(01)00669-3.

DOI:10.1016/s0304-3835(01)00669-3

PMID:11597794

Abstract

There is an evidence to suggest that cdc25B phosphatase is an oncogenic. We hypothesized that cdc25B gene may be expressed in tumors of patients with non-small cell lung cancer (NSCLC) and affect their clinical outcome. Expression of cdc25B messenger RNA was evaluated by reverse transcription polymerase chain reaction in 55 non-small cell lung carcinomas and adjacent histological normal lung samples using LightCycler. The data was analyzed in reference to clinicopathological data and survival data. There was no difference of cdc25B expression level between the NSCLC tissue and normal lung tissue. There was no relationship between cdc25B gene expression and age, gender, N or T-status and clinical stage. However, the NSCLC patients with high cdc25B expression had significantly poor survival than the patients with low cdc25B expression (P=0.0173). Thus we suggest that cdc25B may predict poor survival.

摘要

有证据表明细胞周期蛋白依赖性激酶25B磷酸酶（cdc25B）具有致癌性。我们推测cdc25B基因可能在非小细胞肺癌（NSCLC）患者的肿瘤中表达，并影响其临床预后。使用LightCycler通过逆转录聚合酶链反应在55例非小细胞肺癌及相邻组织学正常的肺组织样本中评估cdc25B信使核糖核酸的表达。参考临床病理数据和生存数据对数据进行分析。NSCLC组织与正常肺组织之间的cdc25B表达水平无差异。cdc25B基因表达与年龄、性别、N或T分期以及临床分期之间无相关性。然而，cdc25B高表达的NSCLC患者的生存率明显低于cdc25B低表达的患者（P=0.0173）。因此我们认为cdc25B可能预示生存率较差。